Ariceum International AG is the Swiss affiliate of Ariceum Therapeutics GmbH, a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of hard-to-treat cancers. Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan.

Products, services, technology

SSO110, 177Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2)  in clinical development stage in neuroendocrine tumours.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business
Core competencies

You may also be interested in